Abstract
Multiple evanescent white dot syndrome (MEWDS) is an inflammatory eye disease which causes decreasing in visual acuity even to 20/400. So far, no molecular pathway has been suggested for MEWDS. Although no exact treatment is suggested for MEWDS, two major medications are being used for treatment already; anti-vascular endothelial growth factor (VEGF) monoclonal anti-bodies and methylprednisolone. Cannabinoids are known as active compounds of Cannabina Sativa with wide variety of biological activities. Methylprednisolone is able to inhibit inflammation through suppressing Interleukin-6 (IL-6), IL-8, and tumor necrosis factor-α (TNF-α). According to the data, cannabinoids are able to inhibit both angiogenesis and inflammation by targeting VEGF, IL-6, IL-8 and TNF-α and other related angiogenic and inflammatory cytokines. Thus herein authors of this study suggest cannabinoids for treatment of MEWDS since it covers both inhibition of angiogenesis and inflammation. However, feature complementary studies are necessary in the field.
Keywords
Angiogenesis Cannabinoids inflammation Multiple Evanescent White Dot Syndrome
Copyright
© 2016, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.